Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: DoNation General Workplace Campaign Scorecard, 0906-XXXX-New, 48186-48187 [2022-16886]
Download as PDF
<![CDATA[
48186
Federal Register / Vol. 87, No. 151 / Monday, August 8, 2022 / Notices
or other forms of information
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022–16898 Filed 8–5–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Information
Collection Request Title: DoNation
General Workplace Campaign
Scorecard, 0906–XXXX—New
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for the opportunity for
public comment on proposed data
collection projects of the Paperwork
Reduction Act of 1995, HRSA
announces plans to submit an
Information Collection Request (ICR),
described below, to the Office of
Management and Budget (OMB). Prior
to submitting the ICR to OMB, HRSA
seeks comments from the public
regarding the burden estimate, below, or
any other aspect of the ICR.
DATES: Comments on this ICR should be
received no later than September 7,
2022.
SUMMARY:
Submit your comments to
paperwork@hrsa.gov or by mail to the
HRSA Information Collection Clearance
Officer, Room 14N136B, 5600 Fishers
Lane, Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
ADDRESSES:
submitted to OMB for review, email
Samantha Miller, the acting HRSA
Information Collection Clearance Officer
at paperwork@hrsa.gov or call (301)
443–9094.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
DoNation General Workplace Campaign
Scorecard OMB No. 0906–XXXX–New.
Abstract: HRSA’s ‘DoNation’
Campaign for Organ Donation will enlist
the help of America’s workplaces to
increase the number of registered organ,
eye, and tissue donors by hosting
awareness, education, outreach, and
donor registration events in their
companies, workplaces, and
communities. This campaign now
incorporates HRSA’s Hospital
Campaign, which encourages America’s
medical facilities and hospitals to
promote organ, eye, and tissue donor
registrations to streamline
communications, better leverage
internal and external resources, and
combine campaign efforts under one
unified and identifiable visual brand
and name. A scorecard identifies
activities that all participants can
implement and assigns points to each
activity. Participants that earn a certain
number of points annually will be
recognized by HRSA and other national
organizations that support the
campaign’s mission. HRSA intends to
create an electronic version of the
scorecard that will be user-friendly and
will collect information from America’s
workplaces regarding their donor
registration and outreach activities. The
scorecard will provide HRSA with data
throughout the campaign year.
Need and Proposed Use of the
Information: There is a substantial
imbalance in the United States between
the number of people whose life
depends on an organ transplant
(currently more than 107,000) and the
annual number of organ donors
(approximately 39,000 living and
deceased donors since January 2020). In
response to the need for increased
donation, HRSA conducts public
outreach initiatives to encourage the
American public to enroll in their state
donor registry as future organ, eye, and
tissue donors.
The scorecard motivates and
facilitates participation in the campaign,
provides the basis for rewarding
participants for their accomplishments,
and enables HRSA to measure and
evaluate the campaign process and
outcome. The scorecard also enables
HRSA to make data-based decisions and
improvements for subsequent
campaigns.
Likely Respondents: Community
development and public relations staff
of organ procurement and other
donation organizations, hospital and
workplace staff and/or leadership, such
as human resources or public relations/
communications professionals and other
staff members, and/or volunteers who
work with workplaces and organizations
on organ donation initiatives.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
khammond on DSKJM1Z7X2PROD with NOTICES
Form name
Number of
responses per
respondent
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Activity Scorecard (electronic PDF) .....................................
1,400
1
1,400
.25
350
Total ..............................................................................
1,400
1
1,400
.25
350
VerDate Sep<11>2014
21:34 Aug 05, 2022
Jkt 256001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
E:\FR\FM\08AUN1.SGM
08AUN1
Federal Register / Vol. 87, No. 151 / Monday, August 8, 2022 / Notices
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022–16886 Filed 8–5–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Deepak Kaushal, Ph.D. (Respondent),
Professor and Director, Southwest
National Primate Research Center, Host
Pathogen Interactions Program, Texas
Biomedical Research Institute (TBRI).
Respondent engaged in research
misconduct in research supported by
U.S. Public Health Service (PHS) funds,
specifically National Institute of Allergy
and Infectious Diseases (NIAID),
National Institutes of Health (NIH),
grants U19 AI111211, R01 AI111943,
R01 AI123047, R01 AI134240, K24
AI058609, and K24 AI114444, and
Office of the Director, NIH, grants P51
OD011104 and P51 OD011133. The
administrative actions, including
supervision for a period of one (1) year,
were implemented beginning on July 22,
2022, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Deepak Kaushal, Ph.D., Texas
Biomedical Research Institute: Based on
the report of an inquiry conducted by
TBRI, Respondent’s admission, and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Deepak Kaushal, Professor and Director,
Southwest National Primate Research
Center, Host Pathogen Interactions
Program, TBRI, engaged in research
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:34 Aug 05, 2022
Jkt 256001
misconduct in research supported by
PHS funds, specifically NIAID, NIH,
grants U19 AI111211, R01 AI111943,
R01 AI123047, R01 AI134240, K24
AI058609, and K24 AI114444, and
Office of the Director, NIH, grants P51
OD011104 and P51 OD011133.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, and/or recklessly falsifying
and fabricating the experimental
methodology to demonstrate results
obtained under different experimental
conditions that were included in the
following one (1) published paper and
two (2) grant applications submitted for
PHS funds:
• Isoniazid and Rifapentine
Treatment Eradicates Persistent
Mycobacterium tuberculosis in
Macaques. Am J Respir Crit Care Med.
2020 Feb 15;201(4):469–77; doi:
10.1164/rccm.201903–0646OC
(hereafter referred to as ‘‘Am J Respir
Crit Care Med 2020’’). Retraction in: Am
J Respir Crit Care Med. 2021 Apr
15;203(8):1045; doi: 10.1164/
rccm.v203retraction1.
• R01 AI159898–01, ‘‘Effect of latent
TB infection on immunity to M.
tuberculosis reinfection,’’ submitted to
NIAID, NIH, on June 25, 2020.
• R01 AI147947–01A1, ‘‘Effect of
prior latent TB infection on immune
responses to M. tuberculosis,’’
submitted to NIAID, NIH, on July 18,
2019.
Specifically, ORI found that
Respondent knowingly, intentionally, or
recklessly:
• Falsified and fabricated the
numbers for treated and untreated nonhuman primates (NHP) used in the
study. The experimental design in Am
J Respir Crit Care Med 2020 falsely
stated that seven NHPs were treated
with 3HP (i.e., a treatment regimen
constituting of twelve once-weekly
doses of 15 mg/kg isoniazid [INH] and
15 mg/kg rifapentine [RPT]) and another
seven NHPs were untreated controls,
when instead a total of eight NHPs were
treated with INH and RPT and six NHPs
were untreated controls.
• Falsified and fabricated the number
of weekly doses of INH and RPT
treatment administered to NHPs in the
study. The experimental design in Am
J Respir Crit Care Med 2020 falsely
stated that seven NHPs were treated
with 3HP, when instead the NHPs were
treated with a variable number of INH
and RPT doses that do not conform to
the 3HP regimen.
• Falsified and fabricated the time
interval between mycobacterium (Mtb)
exposure and the first dose of INH and
RPT treatments that were administered
to NHPs in the study. The experimental
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
48187
design in Am J Respir Crit Care Med
2020 falsely stated that seven NHPs
were treated with 3HP beginning in
Week 16–18 after Mtb infection, when
instead the treated NHPs received the
first dose of INH and RPT treatment at
different time points.
• Falsified and fabricated the time
interval between the last weekly doses
of INH and IPT treatment and infection
with simian immunodeficiency virus
(SIV). The experimental design in
Figure 3A of Am J Respir Crit Care Med
2020 falsely stated that after treatment
with weekly INH and RPT for three
months, NHPs were rested for one
month before coinfection with SIV,
when instead the treated NHPs were
infected with SIV either on the same
day as the last dose of INH and RPT
treatment or at a different time point.
• Included survival kinetics data from
the falsified 3HP treatment in Figure 1G
of Am J Respir Crit Care Med 2020 as
Figure 5 of R01 AI159898–01 to
demonstrate the efficacy of 3HP
treatment against reactivation of latent
Mtb infection in NHPs post SIV
infection.
• Included bacterial persistence and
burden data from the falsified 3HP
treatment in Figures 2A, 2B, and 2C of
Am J Respir Crit Care Med 2020 as
Figure 6C of R01 AI159898–01 and
Figure 2 of R01 AI147947–01A1 to
represent the efficacy of 3HP treatment
in reducing Mtb burden in NHPs post
SIV infection.
• Included pulmonary pathology data
from the falsified 3HP treatment in
Figures 3A and 3B of Am J Respir Crit
Care Med 2020 as Figures 6A and 6B,
respectively, of R01 AI159898–01 to
represent the efficacy of 3HP treatment
against reactivation of latent Mtb
infected NHPs post SIV infection.
• Included clinical parameters from
the falsified 3HP treatment in Figure 1
of Am J Respir Crit Care Med 2020 as
Figure 1 of R01 AI147947–01A1 to
present clinical correlates of latent Mtb
infection and SIV induced reactivation
under 3HP treatment.
• Included pulmonary pathology data
from the falsified 3HP treatment in
Figure 3 of Am J Respir Crit Care Med
2020 as Figure 3 of R01 AI147947–01A1
to represent efficacy of 3HP treatment in
reducing lung pathology due to
reactivation of latent Mtb infection in
NHPs post SIV infection.
• Included untreated NHP’s lung
tissue immunohistochemistry image
representing CD3-positive T-cell
staining from Figure 4B of Am J Respir
Crit Care Med 2020 as Figure 6A of R01
AI147947–01A1 to represent CD3positive T-cell staining in lung tissue of
3HP treated NHPs.
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 87, Number 151 (Monday, August 8, 2022)]
[Notices]
[Pages 48186-48187]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16886]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Proposed Collection:
Public Comment Request; Information Collection Request Title: DoNation
General Workplace Campaign Scorecard, 0906-XXXX--New
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement for the opportunity for
public comment on proposed data collection projects of the Paperwork
Reduction Act of 1995, HRSA announces plans to submit an Information
Collection Request (ICR), described below, to the Office of Management
and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks
comments from the public regarding the burden estimate, below, or any
other aspect of the ICR.
DATES: Comments on this ICR should be received no later than September
7, 2022.
ADDRESSES: Submit your comments to [email protected] or by mail to the
HRSA Information Collection Clearance Officer, Room 14N136B, 5600
Fishers Lane, Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance
requests submitted to OMB for review, email Samantha Miller, the acting
HRSA Information Collection Clearance Officer at [email protected] or
call (301) 443-9094.
SUPPLEMENTARY INFORMATION: When submitting comments or requesting
information, please include the ICR title for reference.
Information Collection Request Title: DoNation General Workplace
Campaign Scorecard OMB No. 0906-XXXX-New.
Abstract: HRSA's `DoNation' Campaign for Organ Donation will enlist
the help of America's workplaces to increase the number of registered
organ, eye, and tissue donors by hosting awareness, education,
outreach, and donor registration events in their companies, workplaces,
and communities. This campaign now incorporates HRSA's Hospital
Campaign, which encourages America's medical facilities and hospitals
to promote organ, eye, and tissue donor registrations to streamline
communications, better leverage internal and external resources, and
combine campaign efforts under one unified and identifiable visual
brand and name. A scorecard identifies activities that all participants
can implement and assigns points to each activity. Participants that
earn a certain number of points annually will be recognized by HRSA and
other national organizations that support the campaign's mission. HRSA
intends to create an electronic version of the scorecard that will be
user-friendly and will collect information from America's workplaces
regarding their donor registration and outreach activities. The
scorecard will provide HRSA with data throughout the campaign year.
Need and Proposed Use of the Information: There is a substantial
imbalance in the United States between the number of people whose life
depends on an organ transplant (currently more than 107,000) and the
annual number of organ donors (approximately 39,000 living and deceased
donors since January 2020). In response to the need for increased
donation, HRSA conducts public outreach initiatives to encourage the
American public to enroll in their state donor registry as future
organ, eye, and tissue donors.
The scorecard motivates and facilitates participation in the
campaign, provides the basis for rewarding participants for their
accomplishments, and enables HRSA to measure and evaluate the campaign
process and outcome. The scorecard also enables HRSA to make data-based
decisions and improvements for subsequent campaigns.
Likely Respondents: Community development and public relations
staff of organ procurement and other donation organizations, hospital
and workplace staff and/or leadership, such as human resources or
public relations/communications professionals and other staff members,
and/or volunteers who work with workplaces and organizations on organ
donation initiatives.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose, or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install, and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the table below.
Total Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total burden
Form name respondents responses per responses response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Activity Scorecard (electronic 1,400 1 1,400 .25 350
PDF)...........................
-------------------------------------------------------------------------------
Total....................... 1,400 1 1,400 .25 350
----------------------------------------------------------------------------------------------------------------
[[Page 48187]]
HRSA specifically requests comments on (1) the necessity and
utility of the proposed information collection for the proper
performance of the agency's functions; (2) the accuracy of the
estimated burden; (3) ways to enhance the quality, utility, and clarity
of the information to be collected; and (4) the use of automated
collection techniques or other forms of information technology to
minimize the information collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022-16886 Filed 8-5-22; 8:45 am]
BILLING CODE 4165-15-P
